Want to see CDNA full AI Analyst Report?
CDNA Stock Chart & Stats
$50.80
-$0.78(-2.10%)
At close: 4:00 PM EDT
$50.80
-$0.78(-2.10%)
Day’s Range― - ―
52-Week Range$14.03 - $72.51
Previous Close$36.37
Volume604.62K
Average Volume (3M)1.35M
Market Cap
$3.47B
Enterprise Value$1.17B
Total Cash (Recent Filing)$373.64M
Total Debt (Recent Filing)$19.25M
Price to Earnings (P/E)32.2
Beta0.93
Next Earnings
Oct 29, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.15
Shares Outstanding51,734,222
10 Day Avg. Volume1,476,434
30 Day Avg. Volume1,353,578
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.31
Price to Sales (P/S)2.64
P/FCF Ratio27.80
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue2.55
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda75.08
Forecast
1Y Price Target
$57.00Price Target Upside12.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.2
Revenue Forecast (FY)$495.12M
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Testing GrowthRapid growth in testing services and total revenue indicates expanding utilization of CareDx’s diagnostic offerings. Higher test volumes, clinical adoption, and broader transplant workflows can support durable revenue growth and operating leverage over the next several quarters.
Raised Guidance And Improving ProfitabilityRaised revenue and EBITDA guidance signals management sees continuing demand and improving economics across the business. Healthy gross margins and operating leverage provide capacity to fund clinical development, commercial expansion, and integration while strengthening earnings potential.
Strong Balance Sheet And Reimbursement PositionA debt-free balance sheet and substantial cash provide flexibility to invest in growth, absorb execution challenges, or pursue strategic opportunities. Finalized Medicare coverage also reduces reimbursement uncertainty and supports broader adoption of the company’s transplant diagnostics.
Bears Say
Inconsistent Historical ProfitabilityRecent profitability is encouraging, but repeated losses across earlier periods reduce confidence that the current earnings level is fully durable. A renewed earnings setback could limit internally funded investment and make operating performance more sensitive to execution or reimbursement changes.
High Operating Expense BurdenA large operating expense base absorbs much of the company’s gross profit and limits near-term margin expansion. Sustaining attractive profitability therefore depends on revenue growth outpacing spending, while additional investments could delay the benefits of operating leverage.
NavDx Integration And Specialty Oncology Execution RiskThe acquisition expands CareDx’s addressable market but introduces execution complexity and a lower-margin revenue mix than transplant testing. Successful systems integration, billing improvement, and ASP expansion are needed for oncology growth to translate into durable margin contribution.
CareDx News
CDNA FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was $14.03 and its highest was $72.51 in the past 12 months.
What is CareDx’s market cap?
CareDx’s market cap is $3.47B.
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Jul 30, 2026. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.232 by $0.138.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is 0.26.
How many shares outstanding does CareDx have?
CareDx has 51,734,222 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of $0.37 in its last earnings report, beating expectations of $0.232. Following the earnings report the stock price went up 14.724%.
Which hedge fund is a major shareholder of CareDx?
Currently, no hedge funds are holding shares in CDNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareDx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$57.00 (12.20% Upside)
$57.00 (12.20% Upside)
Blogger Sentiment
Neutral
CDNA Sentiment 78%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 421.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 40.4%
Last 30 Days ▲ 40.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
354.66%
12-Months-Change
Fundamentals
Return on Equity
32.81%
Trailing 12-Months
Asset Growth
19.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CareDx
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
CDNA Company Deck
CDNA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong organic and inorganic growth, material margin expansion, a fortified balance sheet, and substantive clinical and reimbursement milestones (Medicare LCD, KOAR data, AlloHeme and HistoMap publications). Key near-term risks include sizable operating expense run-rate, material out-of-period revenue that inflated reported margins this quarter, and execution/integration risk around the NavDx acquisition and specialty oncology ASP/margin improvement. Management raised 2026 guidance while taking a conservative approach to NavDx assumptions and flagged potential modest near-term investments that could temper margin expansion. Overall, the positives around revenue growth, cash position, clinical evidence, and coverage developments outweigh the operational and integration cautions.View all CDNA earnings summariesCDNA Stock 12 Month Forecast
Average Price Target
$57.00
▲(12.20% Upside)
Technical Analysis
Ownership Overview
3.56% Insiders
19.83% Mutual Funds
0.40% Other Institutional Investors
53.68% Public Companies and
Individual Investors